PharmiWeb Today Story
Accelerate@Babraham has unveiled its 2025 cohort, selecting five pioneering life science ventures from a competitive pool of 37 applicants—marking a 50% surge in interest. Now in its seventh year, the accelerator at Babraham Research Campus continues to nurture early-stage innovation, having already supported 32 companies and helped raise over £100m.
This year’s cohort includes: AAB Research, developing EV-based cancer therapies; AmnioCam, offering a scalable stem cell-based solution for chronic wound care; Cycle Therapeutics, innovating endometriosis treatment via menstrual fluid analytics; MabGalaxy, using AI to expedite antibody drug discovery; and Sysora Health, tackling gum disease with precision antibacterial gels.
The programme offers an 8-week bespoke curriculum, lab space for a year, £10k funding, and access to a robust support network and facilities. Also joining are three Cambridge NeuroWorks Frontier Fellows via ARIA, aiming to fast-track neurotechnology development.
These ventures now embark on a journey designed to refine their commercial strategies and accelerate towards market readiness, supported by Babraham’s world-class ecosystem.
Read More...
Articles

Top Interview Questions for Medical Writing Jobs
11-Jun-2025

What Does a Pharmaceutical Account Manager Do?
04-Mar-2025

Top 10 Highest Paying Pharma Jobs in 2025
18-Feb-2025

The Impact of AI on Pharmaceutical Sales
13-Feb-2025
Featured Events

-
Next Generation Cancer Vaccine Development Summit…
07-Sep-2021 - 09-Sep-2021 -
Reuters Events: Pharma 2021
11-Oct-2021 - 22-Oct-2021 -
Pharma USA 2022
16-Mar-2022 - 17-Mar-2022 -
Bioprocessing and the future of food
06-Jul-2022 - 07-Jul-2022 -
Reuters Events: Pharma 2022
11-Oct-2022 - 13-Oct-2022 -
Global Biomanufacturing Summit
25-May-2023 - 26-May-2023
News

-
Inka Health Co-Founders Publish New Study Advancin…
20-Jun-2025 -
Action Behavior Centers Hosts Community Impact Eve…
20-Jun-2025 -
Retransmission - Dr. Meegan Gruber Shares Insight…
20-Jun-2025 -
The Dawn of New Beginnings: Navigating the Assiste…
20-Jun-2025 -
DARZALEX® (daratumumab) receives the first positiv…
20-Jun-2025 -
IMBRUVICA® (ibrutinib) receives positive CHMP opin…
20-Jun-2025